MCM
CYTK icon

Manchester Capital Management’s Cytokinetics CYTK Stock Holding History

Manchester Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-720
Closed -$39.6K – 1378
2025
Q3 		$39.6K Hold
720
– – 0.01% 617
2025
Q2 		$23.8K Hold
720
– – ﹤0.01% 689
2025
Q1 		$28.9K Hold
720
– – ﹤0.01% 644
2024
Q4 		$33.9K Buy
720
+50
+7% +$2.6K ﹤0.01% 620
2024
Q3 		$35.4K Buy
670
+120
+22% +$6.69K ﹤0.01% 600
2024
Q2 		$29.8K Buy
+550
New +$33.2K ﹤0.01% 596

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Manchester Capital Management's CYTK Position: Q4 2025 in Review

Manchester Capital Management sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 720 shares — an estimated $39.6K sold.

Manchester Capital Management first reported a position in CYTK in Q2 2024 and held it in 6 quarters. The position peaked at $39.6K in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Manchester Capital Management reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Manchester Capital Management sold 720 Cytokinetics shares in Q4 2025, an estimated $39.6K.
  • Manchester Capital Management first reported a position in Cytokinetics in Q2 2024 and held it in 6 quarters.
  • Manchester Capital Management's Cytokinetics position peaked at $39.6K in Q3 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.